Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Targeted cancer therapy using alpha-cyano-4-hydroxycinnamic acid as a novel vector molecule: A proof-of-concept study

Full text
Author(s):
Calori, Italo Rodrigo [1, 2] ; Piva, Henrique Luis [2] ; Tedesco, Antonio Claudio [2]
Total Authors: 3
Affiliation:
[1] Univ Estadual Maringa, Res Nucleus Photodynam Syst, Dept Chem, Ave Colombo 5790, BR-97020900 Maringa, Parana - Brazil
[2] Univ Sao Paulo, Dept Chem, Ctr Nanotechnol & Tissue Engn, Photobiol & Photomed Res Grp, Fac Philosophy Sci &, BR-14040901 Ribeirao Preto, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY; v. 57, JUN 2020.
Web of Science Citations: 0
Abstract

Up-regulated monocarboxylate transporters (MCTs) serve as potential targets for the development of novel therapeutic strategies against some cancer cells. Besides being an efficient substrate to some MCTs, the role of alpha-cyano-4-hydroxycinnamic acid (CHCA) as a vector of nanoparticles for cancer cells was not yet evaluated. This aim of this study was to demonstrate the role of CHCA as a vector of liposomes targeting cancer cells that overexpress MCT-1. Also, the antioxidant character of CHCA against induced stress oxidative in cancer cell lines was tested. The authors showed that 50 mu M of CHCA led to a significantly enhanced liposome uptake in the MCF-7 and U-87 MG cancer cell lines. Moreover, CHCA decreased MCF-7 cell death from oxidative stress induced by reactive oxygen species generated in situ in a clinical modality known as Photodynamic Therapy. These findings are a proof-of-concept of the role of CHCA as a vector of nanoparticles for targeted cancer therapy. The concept can be explored to develop novel drug delivery systems to target cancer cells of up-regulated MCT-1. Moreover, CHCA-based therapies to avoid oxidative stress can give rise to novel medical treatments. (AU)

FAPESP's process: 13/50181-1 - Use of drugs containing nanocarriers with photosensitizers and/or other active compounds applied to cell therapy and treatment of central nervous system disorders
Grantee:Antonio Claudio Tedesco
Support Opportunities: Research Projects - Thematic Grants